Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

Tagged paragraph iv · clear

UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval

Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted an application seeking FDA approval for a generic version of UroGen's bladder cancer therapy, Jelmyto. The move by Teva…

March 1, 2024Pharma & ANDA2 min read